On the stock market since 1997, it operates in the world of health and science. It has 5,140 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Sales run at $381.1M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 37 buys and 22 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $49.25 — 25% above today’s price.
A loss of $70.8M against $381.1M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, SNDA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SNDA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.